Please assess the completion status of the following clinical trial:

Trial Title: An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent and HIPAA authorization.~* Age between 18 and 65 years~* Male and female subjects with clinically definite or laboratory-supported definite relapsing-remitting multiple sclerosis~* A minimum disease level according to the McDonald criteria for the definition of MS based on results of an MRI scan; acquired within 1 year (Subjects with other significant abnormal findings will be excluded)~* Receiving consistent therapy with Copaxone® or Avonex® for at least 1 year.~* Expanded Disability Status Score (EDSS) of 0 to ≤ 5.5, inclusive~* Exhibiting low or medium level of concern within 12 months prior to screening based on: relapses, or clinical progression, or MRI progression~* Clinical stability or improving neurological state during the eight weeks before Study Day 0~* Willingness \& ability to comply with the protocol for the duration of the study~* Confirmation that a subject capable of having children is not pregnant must be established by a negative urine pregnancy test within 30 days of Screening and a negative urine pregnancy test on Scan Days.~Exclusion Criteria:~* Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception~* Progressive forms of MS (Primary progressive, Secondary progressive)~* Exhibiting a high level of concern within 12 months prior to screening based on: relapses, or clinical progression, or MRI progression~* Subjects who have been on DMTs other than Copaxone® or Avonex® for longer than 3 months~* Subjects who have been on Avonex® or Copaxone® for less than 3 months and have exhibited intolerability~* History of hypersensitivity to natural or recombinant interferon beta, human serum albumin, or any other component of the Avonex® formulation (for Avonex® Group A)~* History of hypersensitivity to glatiramer acetate or mannitol, or any other component of the Copaxone® formulation (for Copaxone® Group B)~* Participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to screening~* Treatment with oral or systemic corticosteroids or ACTH within 4 weeks of screening or ongoing chronic treatment with systemic corticosteroids.~* Treatment with immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporine, methotrexate, azathiprine,linomide, mitoxantrone, Campath) within the 12 months prior to study day 0~* Prior cytokine or anti-cytokine therapy within 3 months prior to Study Day 0~* Prior use of cladribine or have received total lymphoid irradiation~* Have taken intravenous immunoglobulin or any other investigational drug or taken part in any experimental procedure in the 6 months prior to screening~* Psychiatric disorder that is unstable or would preclude safe participation in the study~* Cognitive impairment which impairs ability to understand or comply with the protocol procedures~* Significant leucopenia (white blood cell count \<0.5 times the lower limit of normal)as assessed during the course of routine standard of care~* Elevated liver function tests (ALT, AST, alkaline phosphatase or total bilirubin \>2 times the upper limit of normal) as assessed during the course of routine standard of care~* Specific systemic diseases, (including insulin-dependent diabetes, Lyme disease,clinically significant cardiac disease, HIV, HTLV-1, and Hepatitis B or C), or other uncontrolled major medical conditions (depression, seizure disorder) that would interfere with the participant's safety, compliance or evaluation~* Unable and/or unlikely to follow the protocol for any reason~* Alcohol and/or any other drug abuse~* Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol~* Abnormal baseline clinical findings considered by the investigator to be indicative of conditions that might affect study results~* Impaired renal function, as shown by but not limited to serum creatinine \>2.5 mg/dL~* Subjects who cannot take the FDA approved medication for any reason will be excluded~* Corticosteroids allowed at doses between 500 mg and 1000 mg IV (over 3-5 days for relapses) IV for a maximum of three days~In addition, specific exclusion criteria are required for MRI scanning:~* Ferrous objects within the body~* Pregnancy~* Weight inappropriate for height~* Low visual acuity that cannot be corrected with glasses~* History of claustrophobia~* Participants whose high-resolution anatomic MR scans reveal the presence of a structural abnormality (other than MS).~* Standard protocol for monitoring based on FDA approved medication will be followed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues